Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Chemical Synapses

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Inflammatory myopathies and lymphoma.

Journal of the neurological sciences·2016

Same author

Lymphoma-associated dysimmune polyneuropathies.

Journal of the neurological sciences·2015

Same author

A review on the association between inflammatory myopathies and vaccination.

Autoimmunity reviews·2013

Same author

A literature review on optic neuritis following vaccination against virus infections.

Autoimmunity reviews·2013

Same author

A review of the use of biological agents for chronic inflammatory demyelinating polyradiculoneuropathy.

Journal of the neurological sciences·2013

Same author

Posterior reversible encephalopathy syndrome (PRES) after granulocyte-colony stimulating factor (G-CSF) therapy: a report of 2 cases.

Journal of the neurological sciences·2012

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

Interferon alpha and neuromuscular disorders.

Joerg-Patrick Stübgen¹

¹Department of Neurology and Neuroscience, Weill Medical College of Cornell University/New York Presbyterian Hospital, USA. pstuebge@med.cornell.edu

Journal of Neuroimmunology

|January 28, 2009

Summary

This summary is machine-generated.

Interferon-alpha (IFNalpha) therapy, used for hepatitis C, can trigger autoimmune disorders like neuropathies. Management involves stopping IFNalpha and providing supportive care, though mechanisms remain unclear.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jun 26, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents

Published on: August 10, 2018

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

Immunology
Neurology
Virology

Background:

Interferon-alpha (IFNalpha) is a key protein in host defense and homeostasis.
IFNalpha exhibits antiviral, antiproliferative, and immunomodulatory functions.
Widespread use of IFNalpha, especially for chronic hepatitis C, is linked to autoimmune phenomena.

Purpose of the Study:

To review the autoimmune side effects of Interferon-alpha (IFNalpha) therapy.
To discuss the management of IFNalpha-induced autoimmunity.
To explore the potential therapeutic role of IFNalpha's immunomodulatory effects in neuromuscular diseases.

Main Methods:

Literature review of IFNalpha-induced autoimmunity.
Analysis of case reports and open-label studies on IFNalpha and neuromuscular diseases.
Discussion of proposed mechanisms for IFNalpha-induced autoimmune disorders.

Main Results:

IFNalpha therapy is associated with various autoimmune conditions, including neuropathies, neuromuscular junction disorders, and myopathies.
Management typically involves discontinuing IFNalpha and implementing supportive, immunomodulatory, and symptomatic treatments.
Mechanisms underlying IFNalpha-induced autoimmunity are not fully elucidated and may involve genetic susceptibility.

Conclusions:

IFNalpha can induce or worsen autoimmune disorders, necessitating careful patient monitoring.
Understanding the mechanisms of IFNalpha-induced autoimmunity is crucial for effective management.
Preliminary evidence suggests IFNalpha's immunomodulatory properties might be beneficial for certain immune-mediated neuromuscular diseases, warranting further investigation.